By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Can-Fite BioPharma Ltd. 

Reinhold Cohn House
P.O.Box: 4060
Tel Aviv      Israel
Phone: 03-7109330 Fax: 03-5606405


SEARCH JOBS



Segment
Drug Discovery





Company News
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis 2/8/2017 7:04:09 AM
Can-Fite BioPharma (CFBI) Release: Company Announces $5 Million Registered Direct Offering 1/19/2017 8:11:43 AM
Can-Fite BioPharma (CFBI) Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017 1/9/2017 7:33:28 AM
Can-Fite BioPharma (CFBI) Receives $500,000 Payment As Part Of $3 Million Distribution Deal For Liver Cancer Drug Namodenoson (CF102) In South Korea 12/21/2016 12:28:34 PM
New Preclinical Data Show Can-Fite BioPharma (CFBI)'s Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy In Treatment Of NASH 12/16/2016 9:22:11 AM
Can-Fite BioPharma (CFBI) Reports Financial Results For Nine Months Ended September 30, 2016 & Provides Clinical Update 11/28/2016 7:57:00 AM
American Medical Association's USAN & WHO's INN Approve "Namodenoson" As Generic Name For Can-Fite BioPharma (CFBI)'s Liver Drug CF102 11/16/2016 8:31:39 AM
Can-Fite BioPharma (CFBI) Receives Notice Of Allowance From U.S. Patent And Trademark Office For Erectile Dysfunction Drug 11/10/2016 2:54:53 PM
Can-Fite BioPharma (CFBI) Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA 11/1/2016 6:37:20 AM
Can-Fite BioPharma (CFBI) Signs Distribution Deal For Liver Cancer Drug CF102 In South Korea 10/25/2016 7:03:25 AM
12345678910...
//-->